Waypan-DSR Tablet is a combination pharmaceutical formulation containing Domperidone 30 mg and Pantoprazole 40 mg, designed to manage gastrointestinal disorders effectively. Domperidone, a peripheral dopamine D2 receptor antagonist, facilitates gastric motility and accelerates gastric emptying, thereby alleviating symptoms such as nausea, vomiting, bloating, and gastric discomfort. Pantoprazole, a proton pump inhibitor, suppresses gastric acid secretion by irreversibly inhibiting the H+/K+ ATPase enzyme system in the gastric parietal cells, providing relief from acid-related conditions such as gastroesophageal reflux disease (GERD), erosive esophagitis, and peptic ulcers. The synergistic action of these two agents in Waypan-DSR Tablet offers comprehensive management of upper gastrointestinal symptoms by both enhancing motility and reducing acid secretion. This combination is particularly beneficial in patients with delayed gastric emptying accompanied by acid-related mucosal damage. Waypan-DSR should be administered as prescribed by a healthcare professional, with dosage tailored to individual patient needs. Caution is advised in patients with known hypersensitivity to either component, and it is contraindicated in those with prolactinoma or severe hepatic impairment. Regular monitoring is recommended during prolonged therapy to assess therapeutic response and detect any adverse effects.